by QuantuMDx Team | Dec 13, 2022 | Company Updates, Media Alert, News, Q-POC™
NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay, has been approved for sale in the UK under The Medical Devices (Coronavirus Test Device Approvals) (Amendment)...
by QuantuMDx Team | Nov 22, 2022 | Blog, Company Updates, Media Alert
Preventing Antimicrobial Resistance Together Antimicrobial resistance (AMR) describes the situation when microorganisms (bacteria, fungi, parasites and viruses) no longer respond to the drugs (antimicrobials) that are used to treat infections. As a consequence,...
by QuantuMDx Team | Nov 2, 2022 | Company Updates, Media Alert, News
Agreement will initially cover the UK and France with potential to expand to other European countries and worldwide NEWCASTLE UPON TYNE, UK, 2 November 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point of Care molecular...
by QuantuMDx Team | Sep 6, 2022 | Company Updates, Media Alert, News
The agreement sets a roadmap for the commercialisation of Q-POC™ and its assays in China The two companies will collaborate to accelerate the development of new assays on the Q-POC™ platform Offers potential for component sourcing and manufacturing optimisation...
by QuantuMDx Team | Jul 5, 2022 | Media Alert, News
Diagnosing, treating and managing respiratory infections NEWCASTLE UPON TYNE, UK, 5 July 2022. QuantuMDx Group Limited (“QuantuMDx”) will be offering insights and advice on tackling respiratory infections in the wake of the pandemic during a webinar later this month....
